McDermott Will & Emery is a full-service firm assisting clients in the life sciences and is held in particularly high esteem in the liability and investigations areas. Industry peers were quick to point out the firm's strong work representing Pharmacal, a manufacturer of animal research lab products, in a false claims action as well as the firm's experience representing Amgen in an antitrust case following their acquisition of Onyx. The firm also has extensive experience handling white-collar cases on behalf of major multinational corporations in pharmaceuticals, supplements, diagnostics and animal health. Jeffrey Brennan leads a team that currently serves as antitrust counsel to a pharmaceutical company in a non-public and confidential FTC investigation into a patent settlement agreement. He also served as antitrust counsel to Alnylam Pharmaceuticals before the Federal Trade Commission in connection with Alnylam's 2014 acquisition from Merck of its Sirna Therapeutics subsidiary and RNAi assets. Another DC-based antitrust partner, Ray Jacobsen is representing Impax Laboratories, a publicly-traded, technology-based specialty pharmaceutical company that manufactures and markets both generic and branded products in the generic pharmaceuticals pricing antitrust litigation. This multidistrict litigation, consolidated in the Eastern District of Pennsylvania, consolidates over 70 cases alleging that the leading generic pharmaceutical manufacturers conspired to raise the price of 18 different generic drugs. The class-action litigation stems from a number of government investigations by Congress, state attorneys general, and the DOJ.
